Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-10-23
2007-10-23
Angell, Jon E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
10646391
ABSTRACT:
Treatment of melanoma is achieved through reduction in the effective amount of clusterin in melanoma cells of in a mammalian subject, preferably a human. A therapeutic agent effective to reduce the effective amount of clusterin in the melanoma cells is administered to the subject. The therapeutic agent may be, for example, an antisense ODN or small inhibitory RNA (siRNA) compound targeted to clusterin. bcl-xL in a subject or cell line can also be regulated by administering to the subject or cell line an agent effective to modulate the amount of clusterin expression. In particular, in clusterin expressing cells, the expression of bcl-xL is down-regulated when the effective amount of clusterin is reduced. Such inhibition is significant because bcl-xL is known to act as an inhibitor of apoptosis.
REFERENCES:
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5789389 (1998-08-01), Tarasewicz et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: 6335194 (2002-01-01), Bennett et al.
patent: 6383808 (2002-05-01), Monia et al.
patent: 2002/0128220 (2002-09-01), Gleave
patent: 2003/0158130 (2003-08-01), Gleave et al.
patent: 2004/0053874 (2004-03-01), Monia et al.
patent: 2004/0220131 (2004-11-01), Jackson et al.
patent: WO 99/51259 (1999-10-01), None
patent: WO 00/34469 (2000-06-01), None
patent: WO 00/49937 (2000-08-01), None
patent: WO 01/46455 (2001-06-01), None
patent: WO 02/22635 (2002-03-01), None
patent: WO 03/062421 (2003-07-01), None
patent: WO 03/072591 (2003-09-01), None
patent: WO 2004/018675 (2004-03-01), None
patent: WO 2004/018676 (2004-03-01), None
Branch, A good antisense molecule is hard to find, TIBS, Feb. 1998, pp. 45-50.
Green et al., Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease, J Am Coll Surg, Jul. 2000, vol. 191, No. 1, pp. 93-105.
Jen et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, Stem Cells, 2000, 18:307-319.
Crooke, Antisense Research and Application, Chapter 1, Springer-Verlag, New York, 1998.
Aoki et al., RNA Interference May be More Potent Than Antisense RNA in Human Cancer Cell Lines, 2003, Clinical and Experimental Pharmacology and Physiology, 30, pp. 96-102.
Saijo et al., Pharmokinetics, Tissue Distribution, and Stability of Anitisense Oligodeoxynucleotide Phosphorothioate ISIS 3466 in Mice, 1994, Oncology Research, vol. 6, No. 6, pp. 243-249.
Gleave et al., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, pp. 145-158, vol. 20.
Gleave et al., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, To Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, pp. 39-49, vol. 58, XP-002262320.
Gleave et al., Antisense therapy: Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, pp. 79-92, vol. 21.
Gleave et al., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, pp. 209-221, vol. 4, XP-009021409.
Jones et al., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, pp. 427-431, vol. 34.
Miyake et al., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, pp. 1655-1663, vol. 6, XP-000960694.
Miyake et al., Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer, Cancer Research, 2000, pp. 170-176, vol. 60, XP-002907064.
Miyake et al., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, pp. 4245-4252, vol. 7, XP-002263075.
Miyake et al., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001 , pp. 337-349, vol. 8, XP-002262321.
Sensibar et al., Prevention of Cell Death Induced by Tumor Necrosis Factor a in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin) , Cancer Research, 1995, pp. 2431-2437, vol. 55, XP-002930082.
Rosenberg et al., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, pp. 633-645, vol. 27, No. 7, XP-001002844.
Wilson et al., Clusterin is a secreted mammalian chaperone, TIBS, 2000, pp. 95-97, vol. 25.
Wong et al., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, Eur. J. Biochem, 1994, pp. 917-925, vol. 91, XP-001146404.
Zangemeister-Wittke et al., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, pp. 2547-2555, Volumbe 6, XP-002241562.
Zellweger et al., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2‘O’(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental Therapeutics, 2001, pp. 934-940, vol. 298, No. 3, XP-002262318.
Zellweger et al., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin, Neoplasia, 2001, pp. 360-367, XP-009004604.
Agrawal et al., Antisense Therapeutics: is it as simple as complementary base recognition, Molecular Medicine Today, 2000, pp. 72-81, vol. 6, Publisher: Elsevier Science Ltd.
Aoki et al., RNA Intereference may be more potent than antisense RNA in human cancer cell lines, Clinical and Experimental Pharmacology and Physiology, 2003, pp. 96-102.
Benner et al., Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies, Journal of Pharmacological and Toxicological Methods, 1997, pp. 229-235, Publisher: Elsevier Science Inc.
Boral et al., Clinical evaluation of biologically targeted drugs: obstacles and opportunities, Cancer Chemother Pharmacol, 1998, pp. S3-S21, Publisher: Springer-Verlag.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 1998, pp. 45-50, Publisher: Elsevier Science Ltd.
Steven Brem, MD, Angiogenesis and Cancer Control: From Concept to Therapeutic Trial, Cancer Control Journal, 1999, vol. 6, No. 5, Publisher: H. Lee Moffitt Cancer Center & Research Institute.
Bruchovsky et al., Control of Tumor Progression by Maintenance of Apoptosis, www.prostatepointers.org, 1996, Publisher: Wiley-Liss, Inc.
Buttyan et al., Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death, Molecular and Cellular Biology, 1989, pp. 3473-3481, vol. 9, No. 8, Publisher: American Society for Microbiology.
Cox et al., Angiogenesis and non-small cell lung cancer, Lung Cancer, 2000, pp. 81-100, Publisher: Elsevier.
Crooke et al., Basic principles of antisense therapeutics, Antisense Research and Application, 2004, pp. 1-50, Chapter 1, Publisher: Springer.
Darby et al., Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity, Exp Nephrol, 1995, pp. 234-239, Publisher: S. Karger AG.
Diemer et al., Expression of Porcine Complement Cytolysis Inhibitor mRNA in Cultured Aortic Smooth Muscle Cells, The Journal of Biological Chemistry, Mar. 15, 1992, pp. 5257-5264, vol. 207, No. 8, Publisher: The AMerican Society for Biochemistry and Molecular Biology, Inc.
Genta, New Data Realfirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment, www.genta.co
Gleave Martin
Jansen Burkhard
Angell Jon E.
Bowman Amy H.
Marina Larson & Associates LLC
The University of British Columbia
LandOfFree
Treatment of melanoma by reduction in clusterin levels does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of melanoma by reduction in clusterin levels, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of melanoma by reduction in clusterin levels will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3882342